Literature DB >> 15038690

Quality of life in managed care patients with irritable bowel syndrome.

Alisa Wilson1, George F Longstreth, Kevin Knight, John Wong, Sally Wade, Chiun-Fang Chiou, Victoria Barghout, Feride Frech, Joshua J Ofman.   

Abstract

The relationship between the severity of abdominal discomfort/pain and generic and disease-specific quality of life (QoL) was explored in patients with irritable bowel syndrome in an MCO. Subjects were stratified into four symptom-severity groups. Descriptive and multivariate analyses were used to examine the relationship of QoL to severity of abdominal discomfort/pain. Generic and disease-specific QoL scores declined as severity of abdominal discomfort/pain increased. The lowest 36-Item Short-Form Health Survey scores for respondents with the most severe abdominal discomfort/pain were for role physical (24.2 +/- 35.4) and vitality (33.7 +/- 19.2). In multivariate regression models controlling for age, sex, work status and education, severity of abdominal discomfort/pain was a significant independent predictor of QoL.

Entities:  

Mesh:

Year:  2004        PMID: 15038690

Source DB:  PubMed          Journal:  Manag Care Interface        ISSN: 1096-5645


  16 in total

1.  What level of IBS symptoms drives impairment in health-related quality of life in community subjects with irritable bowel syndrome? Are current IBS symptom thresholds clinically meaningful?

Authors:  Natasha A Koloski; Philip M Boyce; Michael P Jones; Nicholas J Talley
Journal:  Qual Life Res       Date:  2011-08-11       Impact factor: 4.147

2.  Prevalence, impact and attitudes toward lower gastrointestinal dysmotility and sensory symptoms, and their treatment in Canada: A descriptive study.

Authors:  Richard H Hunt; Surinder Dhaliwal; Gervais Tougas; Carmen Pedro; Jean-Francois Labbé; Heidi Paul; Michael Ennamorato
Journal:  Can J Gastroenterol       Date:  2007-01       Impact factor: 3.522

Review 3.  Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment.

Authors:  P Paré; Ronald Bridges; Malcolm C Champion; Subhas C Ganguli; James R Gray; E Jan Irvine; Victor Plourde; Pierre Poitras; Geoffrey K Turnbull; Paul Moayyedi; Nigel Flook; Stephen M Collins
Journal:  Can J Gastroenterol       Date:  2007-04       Impact factor: 3.522

4.  All Roads Lead to Rome: Update on Rome III Criteria and New Treatment Options.

Authors:  David Q Shih; Lola Y Kwan
Journal:  Gastroenterol Rep       Date:  2007       Impact factor: 3.651

Review 5.  An Overview and Proposed Research Framework for Studying Co-Occurring Mental- and Physical-Health Dysfunction.

Authors:  Sarah L Hagerty; Jarrod M Ellingson; Timothy B Helmuth; L Cinnamon Bidwell; Kent E Hutchison; Angela D Bryan
Journal:  Perspect Psychol Sci       Date:  2019-06-07

Review 6.  New treatments for IBS.

Authors:  Magnus Halland; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-11-13       Impact factor: 46.802

Review 7.  Irritable bowel syndrome: a microbiome-gut-brain axis disorder?

Authors:  Paul J Kennedy; John F Cryan; Timothy G Dinan; Gerard Clarke
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

8.  Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome.

Authors:  Dong Hyun Sinn; Ji Hyun Song; Hoi Jin Kim; Jun Haeng Lee; Hee Jung Son; Dong Kyung Chang; Young-Ho Kim; Jae J Kim; Jong Chul Rhee; Poong-Lyul Rhee
Journal:  Dig Dis Sci       Date:  2008-02-15       Impact factor: 3.199

9.  Different associations of health related quality of life with pain, psychological distress and coping strategies in patients with irritable bowel syndrome and inflammatory bowel disorder.

Authors:  Gabriella Seres; Zoltán Kovács; Agota Kovács; Olga Kerékgyártó; Krisztina Sárdi; Pál Demeter; Eszter Mészáros; Ferenc Túry
Journal:  J Clin Psychol Med Settings       Date:  2008-09-30

Review 10.  Cognitive-behavioral therapy for the management of irritable bowel syndrome.

Authors:  Qing-Lin Tang; Guo-Yao Lin; Ming-Qing Zhang
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.